High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.
High-dose intravenous estrogen therapy was shown to be effective in relieving bone pain due to metastatic disease in 22 of 29 (75.9%) men with advanced hormone-resistant prostate cancer. This clinical response was accompanied by significant falls in serum prostate-specific antigen (PSA) levels in 13 (44.8%) patients. It is suggested that this clinical benefit is due to a direct inhibitory effect of estrogen on prostate cancer cells.
Ferro
M A
MA
Department of Urology, Bristol Royal Infirmary, United Kingdom.
Gillatt
D
D
Symes
M O
MO
Smith
P J
PJ
D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000503:physiopathology / Q000556:secondary*; D004054:Diethylstilbestrol / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004054:Diethylstilbestrol; D017430:Prostate-Specific Antigen